Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) will release fourth quarter and year‑end financial results for the period ended December 31, 2025 on March 27, 2026, and will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.

The company emphasizes its commercial‑stage biotechnology platform and notes FDA approval of Symvess (ATEV) for vascular trauma in December 2024 and ongoing late‑stage trials in AV access and PAD.

News Market Reaction – HUMA

+8.61%

18 alerts

+8.61% Session close to close

+6.8% Peak Tracked

-6.1% Trough Tracked

$191.01M Market Cap

1.1x Rel. Volume

In the Mar 23 session, HUMA gained 8.61%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.8% during that session. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.6% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.6% in the session following this news. A strong positive reaction aligns with the company’s transition from development toward commercialization, following FDA approval of Symvess in vascular trauma in December 2024. However, recent history included a $20,000,000 registered direct offering and an at‑the‑market program of up to $60,000,000, both creating dilution overhang. Past events show mixed stock responses to positive clinical and commercial news, so any sharp upside move has contended with financing needs and prior volatility.

Key Figures

Earnings date: March 27, 2026 Earnings call time: 8:00 a.m. Eastern Time BLA approval date: December 2024 +5 more

8 metrics

Earnings date March 27, 2026 Q4 and full-year 2025 results release and business update

Earnings call time 8:00 a.m. Eastern Time Scheduled webcast and conference call on March 27, 2026

BLA approval date December 2024 FDA approval of Symvess BLA in vascular trauma

Registered direct shares 25,000,000 shares Common stock offered per March 19, 2026 424B3

Gross offering size $20,000,000 March 2026 registered direct offering of common stock

Estimated net proceeds $18,400,000 After placement agent fee from March 2026 offering

ATM program size $60,000,000 Common stock at-the-market facility with TD Securities

Shares outstanding 158,835,303 shares Common stock outstanding as of September 30, 2025

Historical Context

5 past events · Latest: Mar 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 19	Purchase commitment	Positive	-19.4%	Saudi hospitals’ binding Symvess purchase commitment for evaluation and outreach.
Mar 19	Equity offering	Negative	-19.4%	Registered direct sale of 25,000,000 shares to raise $20.0 million.
Mar 17	Regulatory filing	Positive	+3.6%	Marketing Authorization Application for Symvess in Israel for vascular trauma.
Mar 02	Investor conferences	Neutral	+0.5%	Participation in March 2026 healthcare investor conferences and webcasts.
Feb 18	Clinical data update	Positive	-5.3%	VESS presentation of 36‑month Symvess safety and efficacy data in trauma.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows sharp selloffs on financing and even some positive clinical or commercial updates, with three aligned reactions and two divergences to news.

Recent Company History

Over recent months, Humacyte has combined clinical and commercial progress for Symvess with significant financing activity. On Feb 18, 2026, strong 36‑month V005 data saw a -5.26% reaction. A conference participation update on Mar 2, 2026 had little impact. In mid‑March, an Israel MAA filing brought a 3.57% move, while a $20.0M registered direct offering and a $1.475M Saudi purchase commitment coincided with a -19.42% decline. Today’s earnings-date announcement arrives after that dilution-driven weakness.

Key Terms

biologics license application, acellular tissue engineered vessel, arteriovenous (av) access, peripheral artery disease, +4 more

8 terms

biologics license application regulatory

"Humacyte’s Biologics License Application for Symvess, the acellular tissue..."

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

acellular tissue engineered vessel medical

"Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma..."

Acellular tissue engineered vessels are lab-made replacement blood vessels created from biological materials but manufactured without living cells, so they act like a ready-made tube that the body can grow into and line with its own cells. For investors, they matter because they target a steady medical need (for example, replacing or bypassing damaged vessels) and carry commercial upside if proven safe and long-lasting, while also involving manufacturing, clinical trial and regulatory risks.

arteriovenous (av) access medical

"late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access..."

A surgical connection created between an artery and a vein so blood can be removed and returned efficiently during kidney dialysis; think of it as installing a durable high-flow hose connection that lets medical teams hook up and run treatment repeatedly without damaging the vessels. Investors care because the quality, durability and complication rate of AV access affect demand for related procedures, medical devices and services, influence healthcare costs and reimbursement, and can drive revenue and liability risks for device makers and dialysis providers.

peripheral artery disease medical

"late-stage clinical trials targeting other vascular applications, including... peripheral artery disease (PAD)."

A circulatory condition in which arteries that supply blood to the legs and feet become narrowed or blocked, reducing blood flow and causing pain, slow healing, or tissue damage—think of it as clogged pipes in the body’s lower limbs. It matters to investors because the prevalence, available treatments, and clinical trial or regulatory outcomes shape demand for drugs, devices, and care services, which can affect revenues, costs and valuation in healthcare-related businesses.

coronary artery bypass graft surgery medical

"The Company is preparing for human clinical study in coronary artery bypass graft surgery..."

A surgical procedure in which a surgeon creates a new pathway for blood to reach the heart by using a healthy blood vessel from elsewhere in the body to bypass a blocked coronary artery—think of it like building a detour around a closed road so traffic (blood) can flow again. It matters to investors because the frequency, cost, recovery time and outcomes of the operation affect hospital and device-maker revenues, demand for related drugs and follow-up care, and can influence long-term healthcare spending and insurer liabilities.

regenerative medicine advanced therapy regulatory

"was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation..."

Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.

fast track designation regulatory

"and has also received FDA Fast Track designation."

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

vascular trauma medical

"in the vascular trauma indication was approved by the FDA in December 2024."

Vascular trauma is injury to arteries or veins caused by accidents, surgical procedures, or violent events that leads to bleeding, clotting, or reduced blood flow to organs and tissues. For investors, it matters because treating these injuries often requires specialized devices, emergency supplies, or surgical services, creating demand drivers, regulatory scrutiny, and reimbursement considerations for companies that make implants, hemostatic products, and vascular repair technologies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

Title	Humacyte 2025 Fourth Quarter and Year End Financial Results and Corporate Update
Date	March 27, 2026
Time	8:00 a.m. Eastern Time
Conference Details	1-877-704-4453 (U.S. Investors) 1-201-389-0920 (International Investors) 13758663 (Conference ID)
Call me™	Click Here
Webcast	Click Here

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is preparing for human clinical study in coronary artery bypass graft surgery, and preclinical development is also underway in the treatment of type 1 diabetes, pediatric heart disease, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

When will Humacyte (HUMA) release Q4 and year‑end 2025 financial results?

Humacyte will release Q4 and year‑end 2025 results on March 27, 2026. According to the company, management will discuss results and provide a corporate update during an 8:00 a.m. ET webcast and conference call that morning.

How can investors join the Humacyte (HUMA) March 27, 2026 webcast and conference call?

Investors can join the webcast or dial the conference lines provided for U.S. and international investors. According to the company, callers should use the conference ID 13758663 or access the webcast link on Humacyte's website.

What regulatory milestone did Humacyte (HUMA) note in the March 23, 2026 announcement?

Humacyte highlighted FDA approval of Symvess (ATEV) for extremity vascular trauma in December 2024. According to the company, other ATEV programs remain investigational and are progressing in late‑stage trials for AV access and PAD.

Will Humacyte (HUMA) discuss clinical programs during the March 27, 2026 call?

Yes, management will provide a corporate update that may cover clinical programs and commercial progress. According to the company, updates may address late‑stage AV access and PAD trials and preparation for additional clinical studies.

What should shareholders expect from Humacyte's (HUMA) March 27, 2026 financial update?

Shareholders should expect Q4 and full‑year financial metrics and commentary on business operations. According to the company, management will present a corporate and financial update via the webcast and make related disclosures during the call.